利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.014 秒)

    Assay for anti-INGAP antibodies
    2.
    发明申请
    Assay for anti-INGAP antibodies 审中-公开

    公开(公告)号：US20070184504A1

    公开(公告)日：2007-08-09

    申请号：US11656357

    申请日：2007-01-22

    申请人： Aaron Vinik ,  David Taylor-Fishwick

    发明人： Aaron Vinik ,  David Taylor-Fishwick

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6854 ,  G01N2333/4733 ,  G01N2333/474 ,  G01N2410/00

    摘要： A solid phase assay is used for detecting antibodies to INGAP104-118 peptide, a 15-amino acid peptide that is the biologically active portion of islet neogenesis associated protein (INGAP). The isotype of the antibodies to INGAP104-118 peptide can be determined. A kit can also be used in the detection of anti-INGAP104-118 antibodies. Endogenous autoantibodies or antibody production during therapeutic treatment of a mammal with INGAP104-118 can be monitored.

    TREATMENT OF DIABETES AND DISORDERS ASSOCIATED WITH VISCERAL OBESITY WITH INHIBITORS OF HUMAN ARACHIDONATE 12 LIPOXYGENASE AND ARACHIDONATE 15-LIPOXYGENASE
    4.
    发明申请
    TREATMENT OF DIABETES AND DISORDERS ASSOCIATED WITH VISCERAL OBESITY WITH INHIBITORS OF HUMAN ARACHIDONATE 12 LIPOXYGENASE AND ARACHIDONATE 15-LIPOXYGENASE 审中-公开
    治疗与人类ARACHIDONATE抑制剂相关的糖尿病和糖尿病12 LIPOXYGENASE和ARACHIDONATE 15-LIPOXYGENASE

    公开(公告)号：US20130131140A1

    公开(公告)日：2013-05-23

    申请号：US13522165

    申请日：2011-01-14

    申请人： Jerry L. Nadler ,  David Taylor-Fishwick ,  Swarup Chakrabarti ,  Anca Dobrian

    发明人： Jerry L. Nadler ,  David Taylor-Fishwick ,  Swarup Chakrabarti ,  Anca Dobrian

    IPC分类号： C12N15/113 ,  C12Q1/02

    CPC分类号： C12N15/1137 ,  C12Q1/025 ,  C12Q1/26 ,  G01N2333/90241 ,  G01N2800/042

    摘要： A basis for understanding the arachidonate 12-lipoxygenase pathway, as well as and methods and kits for inhibiting the arachidonate 12-lipoxygenase pathway for the treatment, reversal, reduction, modulation or prevention of disease states and conditions related to type 1 or type 2 diabetes, are disclosed. Also disclosed are inflammatory forms of ALOX12 and 15, which are selectively expressed in omental adipose tissue of obese humans. Inhibitors of ALOX12 and 15 can be used to treat, prevent, modulate or reduce complications associated with increased visceral obesity and inflammation, including type 2 diabetes. Also disclosed are methods for developing selective ALOX inhibitors for treating or reducing complications associated with increased visceral obesity and inflammation.

    摘要翻译： 了解花生四烯酸12脂氧合酶途径的基础，以及用于抑制花生四烯酸12-脂氧合酶途径用于治疗，逆转，减少，调节或预防与1型或2型糖尿病有关的疾病状态和病症的方法和试剂盒 ，被披露。 还公开了ALOX12和15的炎性形式，其在肥胖人的网膜脂肪组织中选择性表达。 ALOX12和15的抑制剂可用于治疗，预防，调节或减少与内脏肥胖和炎症（包括2型糖尿病）相关的并发症。 还公开了用于开发用于治疗或减少与内脏肥胖和炎症增加相关的并发症的选择性ALOX抑制剂的方法。